(Q28377666)

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900318-1

Bile acid metabolism and the pathophysiology of cholestasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900318-1

Ursodiol for hepatobiliary disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900318-1

Effects of bile acids and cholestasis on major histocompatibility complex class I in human and rat hepatocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900318-1

Clinical pharmacokinetics of therapeutic bile acids.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900318-1

Ursodeoxycholic acid in the treatment of cholesterol cholelithiasis. part I

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900318-1

Molecular aspects of membrane stabilization by ursodeoxycholate [see comment]

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900318-1

Serum bile acids in primary biliary cirrhosis: effect of ursodeoxycholic acid therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900318-1

Hepatic expression of class I and class II major histocompatibility complex molecules in primary biliary cirrhosis: effect of ursodeoxycholic acid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900318-1

Nonalcoholic steatohepatitis: An expanded clinical entity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900318-1

Nonalcoholic Steatohepatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900318-1

Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900318-1

Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900318-1

Management of primary biliary cirrhosis and autoimmune cholangitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900318-1

Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900318-1

Histopathological study of primary biliary cirrhosis and the effect of ursodeoxycholic acid treatment on histology progression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900318-1

Cost-effectiveness of ursodeoxycholic acid therapy in primary biliary cirrhosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900318-1

A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900318-1

Primary sclerosing cholangitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900318-1

The management of primary sclerosing cholangitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900318-1

Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900318-1

Efficacy of ursodeoxycholic acid treatment and endoscopic dilation of major duct stenoses in primary sclerosing cholangitis. An 8-year prospective study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900318-1

Ursodeoxycholic acid in the treatment of liver diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900318-1

The enigma of intrahepatic cholestasis of pregnancy: lessons from Chile.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900318-1

Intrahepatic cholestasis of pregnancy: a French prospective study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900318-1

Effects of ursodeoxycholic acid in patients with intrahepatic cholestasis of pregnancy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900318-1

Ursodeoxycholic acid in the treatment of cholestasis of pregnancy: a randomized, double-blind study controlled with placebo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900318-1

Ursodeoxycholic acid treatment of refractory chronic graft-versus-host disease of the liver

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900318-1

Cholestatic liver diseases in adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900318-1

Ursodeoxycholic acid for liver disease associated with cystic fibrosis: a double-blind multicenter trial. The Italian Group for the Study of Ursodeoxycholic Acid in Cystic Fibrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900318-1

Scintigraphic documentation of an improvement in hepatobiliary excretory function after treatment with ursodeoxycholic acid in patients with cystic fibrosis and associated liver disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900318-1

Ursodeoxycholate increases cytosolic calcium concentration and activates Cl- currents in a biliary cell line

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900318-1

Ursodeoxycholic acid therapy in cystic fibrosis-associated liver disease: a dose-response study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900318-1

Is ursodeoxycholic acid an effective therapy for total parenteral nutrition-related liver disease?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900318-1

Failure of ursodeoxycholic acid to prevent acute cellular rejection after liver transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900318-1

The Nordic multicenter double-blind randomized controlled trial of prophylactic ursodeoxycholic acid in liver transplant patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900318-1

A randomized clinical trial of ursodeoxycholic acid as adjuvant treatment to prevent liver transplant rejection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900318-1

Ursodiol prophylaxis against hepatic complications of allogeneic bone marrow transplantation. A randomized, double-blind, placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900318-1

Ursodeoxycholic acid therapy of chronic cholestatic conditions in adults and children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900318-1

Treatment of chronic hepatitis C with interferon with or without ursodeoxycholic acid: a randomized prospective trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900318-1